Data / Drug companies / Nordic Pharma, Inc.
Nordic Pharma, Inc.: 21 products in the FDA NDC directory, labeler code 69918
Nordic Pharma, Inc. (labeler code 69918) lists 21 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 21 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 31, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69918
- Products in commercial distribution
- 21
- Packages
- 23
- Finished drugs by generic name
- 9
- Prescription products
- 21
- Over the counter products
- 0
- Flagged as original packager
- 19 of 19 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- December 10, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 12 | 57.1% |
| New drug applications (NDA) | 7 | 33.3% |
| Authorized generics (NDA) | 2 | 9.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 21 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Desmopressin acetate | 7 | 27 |
| Lamotrigine | 4 | 51 |
| Isoproterenol hydrochloride | 4 | 13 |
| Tranexamic acid | 1 | 39 |
| Mesalamine | 1 | 41 |
| Timolol maleate | 1 | 20 |
| Neomycin sulfate, polymyxin b sulfate and dexamethasone | 1 | 11 |
| Arsenic trioxide | 1 | 21 |
| Succinylcholine chloride | 1 | 27 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 7 | 33.3% |
| Solution | 6 | 28.6% |
| Injection, solution | 6 | 28.6% |
| Suppository | 1 | 4.8% |
| Suspension | 1 | 4.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Neomycin sulfate, polymyxin b sulfate and dexamethasone | 69918-515 | Suspension | Authorized generics (NDA) | March 31, 2025 |
| Isoproterenol Hydrochloride | 69918-735 | Injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Isoproterenol Hydrochloride | 69918-731 | Injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Succinylcholine Chloride | 69918-700 | Injection, solution | Generic drugs (ANDA) | May 20, 2024 |
| Desmopressin Acetate | 69918-901 | Solution | New drug applications (NDA) | May 9, 2022 |
| Timoptic in Ocudose | 69918-601 | Solution | Generic drugs (ANDA) | February 26, 2022 |
| Lamotrigine | 69918-380 | Tablet | Generic drugs (ANDA) | February 14, 2022 |
| Lamotrigine | 69918-370 | Tablet | Generic drugs (ANDA) | February 14, 2022 |
| Lamotrigine | 69918-360 | Tablet | Generic drugs (ANDA) | February 14, 2022 |
| Lamotrigine | 69918-350 | Tablet | Generic drugs (ANDA) | February 14, 2022 |
| Desmopressin Acetate | 69918-901 | Solution | New drug applications (NDA) | January 7, 2022 |
| Desmopressin Acetate | 69918-899 | Solution | New drug applications (NDA) | January 7, 2022 |
| Isoproterenol Hydrochloride | 69918-735 | Injection, solution | Generic drugs (ANDA) | August 1, 2021 |
| Isoproterenol Hydrochloride | 69918-731 | Injection, solution | Generic drugs (ANDA) | August 1, 2021 |
| Mesalamine Rectal | 69918-560 | Suppository | Generic drugs (ANDA) | June 24, 2019 |
| Arsenic trioxide | 69918-720 | Injection, solution | Generic drugs (ANDA) | November 14, 2018 |
| Tranexamic Acid | 69918-301 | Tablet | Authorized generics (NDA) | March 1, 2016 |
| Desmopressin Acetate | 69918-901 | Solution | New drug applications (NDA) | January 20, 2016 |
| Desmopressin Acetate | 69918-899 | Solution | New drug applications (NDA) | January 20, 2016 |
| Desmopressin Acetate | 69918-201 | Tablet | New drug applications (NDA) | December 10, 2015 |
| Desmopressin Acetate | 69918-101 | Tablet | New drug applications (NDA) | December 10, 2015 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.